Vaccines shine for CSL

CSL chief executive Paul Perreault (source; CSL)
In “difficult global environment” vaccines division managed 16% profit increase CSL’s newly-renamed vaccines division CSL Seqirus has been one of the brightest divisions for the Australian pharmaceutical giant, with both its revenue and profits into double digits. While posting an overall five per cent drop in profit to $USD 2.25 billion ($AUD 3.23 billion) for

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous World news wrapup: 18 August 2022
Next NMP review is back